Literature DB >> 25111426

Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.

Willemina R R Geurts-Giele1, Celine H M Leenen, Hendrikus J Dubbink, Isabelle C Meijssen, Edward Post, Hein F B M Sleddens, Ernst J Kuipers, Anne Goverde, Ans M W van den Ouweland, Margot G F van Lier, Ewout W Steyerberg, Monique E van Leerdam, Anja Wagner, Winand N M Dinjens.   

Abstract

Lynch syndrome (LS) is caused by germline mutations in mismatch repair (MMR) genes, resulting in microsatellite-unstable tumours. Approximately 35% of suspected LS (sLS) patients test negative for germline MMR gene mutations, hampering conclusive LS diagnosis. The aim of this study was to investigate somatic MMR gene aberrations in microsatellite-unstable colorectal and endometrial cancers of sLS patients negative for germline MMR gene mutations. Suspected LS cases were selected from a retrospective Clinical Genetics Department diagnostic cohort and from a prospective multicentre population-based study on LS in The Netherlands. In total, microsatellite-unstable tumours of 40 sLS patients (male/female 20/20, median age 57 years) were screened for somatic MMR gene mutations by next-generation sequencing. In addition, loss of heterozygosity (LOH) of the affected MMR genes in these tumours as well as in 68 LS-associated tumours and 27 microsatellite-unstable tumours with MLH1 promoter hypermethylation was studied. Of the sLS cases, 5/40 (13%) tumours had two pathogenic somatic mutations and 16/40 (40%) tumours had a (likely) pathogenic mutation and LOH. Overall, LOH of the affected MMR gene locus was observed in 24/39 (62%) tumours with informative LOH markers. Of the LS cases and the tumours with MLH1 promoter hypermethylation, 39/61 (64%) and 2/21 (10%) tumours, respectively, demonstrated LOH. Half of microsatellite-unstable tumours of sLS patients without germline MMR gene mutations had two (likely) deleterious somatic MMR gene aberrations, indicating their sporadic origin. Therefore, we advocate adding somatic mutation and LOH analysis of the MMR genes to the molecular diagnostic workflow of LS.
Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  Lynch syndrome; colorectal cancer; germline mutation; mismatch repair deficiency

Mesh:

Year:  2014        PMID: 25111426     DOI: 10.1002/path.4419

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  48 in total

1.  RNA analysis of cancer predisposing genes in formalin-fixed paraffin-embedded tissue determines aberrant splicing.

Authors:  Anne Ml Jansen; Heleen M van der Klift; Marieke Ae Roos; Jaap Dh van Eendenburg; Carli Mj Tops; Juul T Wijnen; Frederik J Hes; Hans Morreau; Tom van Wezel
Journal:  Eur J Hum Genet       Date:  2018-04-30       Impact factor: 4.246

2.  Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes.

Authors:  Brian H Shirts; Eric Q Konnick; Sarah Upham; Tom Walsh; John Michael O Ranola; Angela L Jacobson; Mary-Claire King; Rachel Pearlman; Heather Hampel; Colin C Pritchard
Journal:  Am J Hum Genet       Date:  2018-06-07       Impact factor: 11.025

3.  Clinical characteristics of patients with colorectal cancer with double somatic mismatch repair mutations compared with Lynch syndrome.

Authors:  Rachel Pearlman; Sigurdis Haraldsdottir; Albert de la Chapelle; Jon G Jonasson; Sandya Liyanarachchi; Wendy L Frankel; Thorunn Rafnar; Kari Stefansson; Colin C Pritchard; Heather Hampel
Journal:  J Med Genet       Date:  2019-03-15       Impact factor: 6.318

4.  DNA mismatch repair protein deficient non-neoplastic colonic crypts: a novel indicator of Lynch syndrome.

Authors:  Rish K Pai; Beth Dudley; Eve Karloski; Randall E Brand; Neil O'Callaghan; Christophe Rosty; Daniel D Buchanan; Mark A Jenkins; Stephen N Thibodeau; Amy J French; Noralane M Lindor; Reetesh K Pai
Journal:  Mod Pathol       Date:  2018-06-08       Impact factor: 7.842

Review 5.  Laboratory Assays in Evaluation of Lynch Syndrome in Patients with Endometrial Carcinoma.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Surg Pathol Clin       Date:  2016-04-11

6.  Targeted next generation sequencing screening of Lynch syndrome in Tunisian population.

Authors:  Rihab Ben Sghaier; Anne Maria Lucia Jansen; Ahlem Bdioui; Tom Van Wezel; Mehdi Ksiaa; Lamia Elgolli; Leila Ben Fatma; Slim Ben Ahmed; Mohamed Msaddak Azzouz; Olfa Hellara; Amine Elghali; Fathi Darbel; Karim Skandrani; Moncef Mokkni; Ameni Gdissa; Rached Ltaief; Ali Saad; Fahmi Hmila; Moez Gribaa; Hans Morreau
Journal:  Fam Cancer       Date:  2019-07       Impact factor: 2.375

7.  Identification of MSH2 inversion of exons 1-7 in clinical evaluation of families with suspected Lynch syndrome.

Authors:  Maureen E Mork; Andrea Rodriguez; Melissa W Taggart; Miguel A Rodriguez-Bigas; Patrick M Lynch; Sarah A Bannon; Y Nancy You; Eduardo Vilar
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

8.  Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome.

Authors:  Jessica A Hemminger; Rachel Pearlman; Sigurdis Haraldsdottir; Deborah Knight; Jon Gunnlaugur Jonasson; Colin C Pritchard; Heather Hampel; Wendy L Frankel
Journal:  Hum Pathol       Date:  2018-05-01       Impact factor: 3.466

9.  Clinical Challenges Associated with Universal Screening for Lynch Syndrome-Associated Endometrial Cancer.

Authors:  Amanda S Bruegl; Kari L Ring; Molly Daniels; Bryan M Fellman; Diana L Urbauer; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2016-12-13

10.  Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort.

Authors:  Kari L Ring; Amanda S Bruegl; Brian A Allen; Eric P Elkin; Nanda Singh; Anne-Renee Hartman; Molly S Daniels; Russell R Broaddus
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.